CN108291228A - C/EBPαSARNA组合物和使用方法 - Google Patents

C/EBPαSARNA组合物和使用方法 Download PDF

Info

Publication number
CN108291228A
CN108291228A CN201680034224.1A CN201680034224A CN108291228A CN 108291228 A CN108291228 A CN 108291228A CN 201680034224 A CN201680034224 A CN 201680034224A CN 108291228 A CN108291228 A CN 108291228A
Authority
CN
China
Prior art keywords
sarna
pharmaceutical composition
cell
ebp
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680034224.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·瓦格纳
R·哈比卜
H·E·胡贝尔
P·萨特罗姆
E·B·斯图夫纳
M·霍斯巴赫
M·卡兰波特
H-P·沃尔洛赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mina Therapeutics Ltd
Original Assignee
Mina Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mina Therapeutics Ltd filed Critical Mina Therapeutics Ltd
Priority to CN202210140475.5A priority Critical patent/CN114525279A/zh
Publication of CN108291228A publication Critical patent/CN108291228A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680034224.1A 2015-04-22 2016-04-21 C/EBPαSARNA组合物和使用方法 Pending CN108291228A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210140475.5A CN114525279A (zh) 2015-04-22 2016-04-21 C/EBP α SARNA组合物和使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562150889P 2015-04-22 2015-04-22
US62/150,889 2015-04-22
US201562235778P 2015-10-01 2015-10-01
US62/235,778 2015-10-01
US201662308521P 2016-03-15 2016-03-15
US62/308,521 2016-03-15
PCT/GB2016/051117 WO2016170349A1 (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210140475.5A Division CN114525279A (zh) 2015-04-22 2016-04-21 C/EBP α SARNA组合物和使用方法

Publications (1)

Publication Number Publication Date
CN108291228A true CN108291228A (zh) 2018-07-17

Family

ID=55948895

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680034224.1A Pending CN108291228A (zh) 2015-04-22 2016-04-21 C/EBPαSARNA组合物和使用方法
CN202210140475.5A Pending CN114525279A (zh) 2015-04-22 2016-04-21 C/EBP α SARNA组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210140475.5A Pending CN114525279A (zh) 2015-04-22 2016-04-21 C/EBP α SARNA组合物和使用方法

Country Status (8)

Country Link
US (2) US10912790B2 (enExample)
EP (1) EP3286316A1 (enExample)
JP (4) JP6768701B2 (enExample)
KR (2) KR102599712B1 (enExample)
CN (2) CN108291228A (enExample)
AU (3) AU2016251415B9 (enExample)
SG (1) SG11201707683YA (enExample)
WO (1) WO2016170349A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306367A (zh) * 2021-08-27 2022-04-12 赵小洋 一种含有C/EBPα-saRNA的组合物
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112220797B (zh) * 2013-11-22 2023-11-03 米纳治疗有限公司 C/EBPα组合物和使用方法
JP2020501545A (ja) * 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのｒｎａ
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
WO2019048645A1 (en) * 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
CN108103108A (zh) * 2018-01-30 2018-06-01 上海交通大学医学院附属瑞金医院 Cebpa基因缺失斑马鱼突变体的制备及其应用
WO2019158720A1 (en) 2018-02-16 2019-08-22 Mina Therapeutics Limited C/ebp alpha sarna compositions and methods of use
CN116121246A (zh) * 2018-04-10 2023-05-16 中美瑞康核酸技术(南通)研究院有限公司 一种新型小激活rna
WO2019239144A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
WO2021021713A1 (en) * 2019-07-26 2021-02-04 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
CA3148593A1 (en) * 2019-07-29 2021-02-04 Brightseed, Inc. Method for improving digestive health
JP2022552940A (ja) * 2019-09-20 2022-12-21 ラクティゲン セラピューティクス 血小板減少症を治療するための核酸分子及びその応用
US20220404338A1 (en) * 2019-12-03 2022-12-22 Merck Sharp & Dohme Llc In vitro cell based potency assay
GB202019692D0 (en) * 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions
US20240091333A1 (en) 2020-12-28 2024-03-21 Douglas T. Gjerde Temperature Stable Nucleic Acid Method for Preparing Vaccines
WO2022166814A1 (zh) * 2021-02-07 2022-08-11 中美瑞康核酸技术(南通)研究院有限公司 一种化学修饰的小激活rna
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
KR102428121B1 (ko) * 2021-10-20 2022-08-08 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템
US20240207204A1 (en) * 2022-12-12 2024-06-27 Regeneron Pharmaceuticals, Inc. Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists
WO2024134199A1 (en) * 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024165876A2 (en) * 2023-02-10 2024-08-15 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
WO2024175887A1 (en) 2023-02-22 2024-08-29 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR20240138691A (ko) * 2023-03-13 2024-09-20 부산대학교 산학협력단 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법
TW202502303A (zh) * 2023-06-29 2025-01-16 美商瑞佩爾托利免疫醫藥股份有限公司 用於遞送有效載荷之脂質粒子
WO2025052098A1 (en) 2023-09-08 2025-03-13 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
WO2025224036A1 (en) * 2024-04-22 2025-10-30 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102612560A (zh) * 2009-06-16 2012-07-25 欧科库尔纳有限责任公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
CN103201384A (zh) * 2010-06-23 2013-07-10 米纳治疗有限公司 Rna分子及其应用
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US20110281270A1 (en) 2008-11-13 2011-11-17 Erasmus University Medical Center Rotterdam Efficient detection of double mutants of the cebpa gene in acute myeloid leukemia
CA2817256A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
DE102011079572B4 (de) * 2011-07-21 2024-12-05 Endress+Hauser Conducta Gmbh+Co. Kg Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums
CA2890725A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
US20150299804A1 (en) * 2012-11-15 2015-10-22 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
CA2991052A1 (en) * 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102612560A (zh) * 2009-06-16 2012-07-25 欧科库尔纳有限责任公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
CN103201384A (zh) * 2010-06-23 2013-07-10 米纳治疗有限公司 Rna分子及其应用
CN103842508A (zh) * 2011-06-21 2014-06-04 米纳治疗有限公司 白蛋白产生和细胞增殖
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies
WO2015075557A2 (en) * 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VIKASH REEBYE等: "Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo", 《HEPATOLOGY》 *
黄光存: "C/EBP-α基因在大鼠肝星状细胞激活中的作用", 《中国优秀博硕士学位论文全文数据库 (博士) 医药卫生科技辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306367A (zh) * 2021-08-27 2022-04-12 赵小洋 一种含有C/EBPα-saRNA的组合物
CN118480552A (zh) * 2024-01-18 2024-08-13 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Also Published As

Publication number Publication date
CA2980975A1 (en) 2016-10-27
KR20170136542A (ko) 2017-12-11
CN114525279A (zh) 2022-05-24
AU2016251415B9 (en) 2019-05-23
KR102599712B1 (ko) 2023-11-09
US20210187007A1 (en) 2021-06-24
AU2022202355A1 (en) 2022-04-28
KR102760315B1 (ko) 2025-02-04
US10912790B2 (en) 2021-02-09
JP2021000119A (ja) 2021-01-07
AU2019210578A1 (en) 2019-08-22
AU2016251415B2 (en) 2019-05-02
EP3286316A1 (en) 2018-02-28
JP6768701B2 (ja) 2020-10-14
WO2016170349A1 (en) 2016-10-27
JP2018516545A (ja) 2018-06-28
AU2019210578B2 (en) 2022-01-13
JP2021192616A (ja) 2021-12-23
JP6931733B2 (ja) 2021-09-08
US20200376020A1 (en) 2020-12-03
KR20230156961A (ko) 2023-11-15
JP2024079713A (ja) 2024-06-11
SG11201707683YA (en) 2017-11-29
AU2016251415A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
JP6931733B2 (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
JP6946399B2 (ja) Ｃ／ＥＢＰα低分子活性化ＲＮＡ
US20230031703A1 (en) Stabilized hnf4a sarna compositions and methods of use
EP3679140B1 (en) Stabilized cebpa sarna compositions and methods of use
WO2015162422A1 (en) Sarna compositions and methods of use
JP7525578B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
CA2980975C (en) C/ebp alpha sarna compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180717